New number of shares and votes in Swedish Orphan Biovitrum AB (publ)

The total number of shares in Swedish Orphan Biovitrum AB (publ) as per 31 July
2014 amounts to 270,785,950 shares, whereof 270,389,770 common shares and
396,180 class C shares, corresponding to in total 270,429,388 votes. The
increase in the number of shares and votes results from an issue of 396,180
class C shares under Swedish Orphan Biovitrum's incentive program. The class C
shares are intended to ensure fulfillment of commitments under incentive
programs. The company holds 4,688,948 common shares and all 396,180 class C
shares.

---

About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on Inflammation and Genetic diseases, with two late stage biological
development projects within Haemophilia. We also market a portfolio of specialty
and rare disease products for partner companies. Sobi is a pioneer in
biotechnology with world-class capabilities in protein biochemistry and
biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion
($334 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com.

For more information please contact
Media relations                                 Investor relations
Oskar Bosson                                  Jörgen Winroth,
Head of Communications                 Vice President, Head of Investor
Relations
T: +46 70 410 71 80                         T: +1 347-224-0819, +1 212-579-0506
oskar.bosson@sobi.com                  jorgen.winroth@sobi.com


The above information has been made public in accordance with the Swedish
Securities Market Act and/or the Financial Instruments Trading Act. The
information was released for public distribution on 31 July 2014 at 08:00 CET.


[HUG#1830796]